We have a strong vision to develop effective and sustainable drugs based on original discoveries on body’s own anti-infective defenses. Today, there are no drugs that reduce severe inflammation and organ damage in patients with ARDS and septic shock. Moreover, in the approaching “post-antibiotic era”, antibiotics will have much decreased efficacy. The new drug developed by Transient Pharma AB will address a significant unmet need, and has therefore a huge clinical potential.
Menu